ArticleScientific reports2025
Differentiation of acute-phase AQP4-IgG+ optic neuritis from CNS inflammatory diseases using optic nerve head blood flow analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of risk factors for relapse at initial onset in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis using ophthalmic findings.Japanese journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Early diagnosis of optic neuritis (ON) associated with aquaporin-4 immunoglobulin-G (AQP4-IgG), myelin oligodendrocyte glycoprotein immunoglobulin-G (MOG-IgG), or multiple sclerosis (MS) is challenging due to invasive and time-consuming tests. We investigated whether ophthalmologic assessments, including laser speckle flowgraphy (LSFG) and optical coherence tomography (OCT), are useful for distinguishing among these diseases at ON onset. This retrospective study included 10 AQP4-IgG+ON patients, 20 MOG-IgG+ON patients, 9 MS-ON patients, and 27 idiopathic ON (ION) patients at initial onset, and 66 propensity-score-matched control eyes. We measured mean blur rate (MBR), representing blood flow velocity, using LSFG and assessed optic nerve head (ONH) vessel-area MBR (ONH-MV), tissue-area MBR (ONH-MT), and peripapillary choroidal MBR. Circumpapillary retinal nerve fiber layer (cpRNFL) thickness was measured with OCT. We found that MOG-IgG+ON patients had a significantly thicker cpRNFL than AQP4-IgG+ON patients and controls (P < 0.05). AQP4-IgG+ON and MOG-IgG+ON patients had significantly lower ONH-MV than controls (P ≤ 0.001). AQP4-IgG+ON patients had significantly lower ONH-MT than MOG-IgG+ON, MS-ON, ION patients, or controls, and lower choroidal MBR than controls (P < 0.05). A receiver operating characteristic analysis combining cpRNFL thickness, ONH-MV, ONH-MT, and choroidal MBR achieved an area under the curve of 0.892 in differentiating AQP4-IgG+ON from other diseases (P < 0.001). LSFG and OCT could distinguish AQP4-IgG+ON from other diseases at onset non-invasively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.